I enjoyed a scientific seminar from Prof Peter Gunning mid last year. I'm pleased Novogen continues to make such good progress on the ATM drug. It's pleasing that with the ATM drug so very promising the company thinks their other line of drugs, SBPs, is at least as good.
The scientific results from the original ATM compound (not the optimised one just used) were simply stunning. They had been validated by multiple labs using differing techniques at that point. With other Biotechs I sometimes worry on the quality of proof behind their pre-clinical work -- no concern in Novogen's case. Some other companies seem quite shy at proving scientifically that they have the goods.
NRT Price at posting:
20.5¢ Sentiment: Hold Disclosure: Held
